UP-7 A Canadian Consensus Forum on the Management of Patients with Prostate Cancer
Thursday June 27, 2019 from
Award Winner
Fred Saad, Canada has been granted the

Fred Saad, Canada

Professor and Chief of Urology


University of Montreal Health Centre (CHUM)


A Canadian Consensus Forum on the Management of Patients with Prostate Cancer

Fred Saad1, Bobby Shayegan2, Tamim Niazi3, Krista Noonan4, Shawn Malone5, Antonio Finelli6, Alan I. So7, Brita Danielson8, Kim Chi4, Sebastien Hotte9.

1Centre Hospitalier de l’Université de Montréal, University of Montreal, Montreal, QC, Canada; 2St. Joseph’s Healthcare, McMaster University, Hamilton, ON, Canada; 3Jewish General Hospital, McGill University, Montreal, QC, Canada; 4BC Cancer Agency, University of British Columbia, Surrey, BC, Canada; 5The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; 6Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; 7Prostate Centre at Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada; 8Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; 9Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada

Naveen S Basappa. Ilias Cagiannos. Christina Canil. Guila Delouya. Ricardo Fernandes. Cristiano Ferrario. Geoffrey T Gotto. Robert J Hamilton. Jason P Izard. Anil Kapoor. Daniel Khalaf. Michael Kolinsky. Aly-Khan Lalani. Luke T Lavallée. Christopher Morash. Scott C Morgan. Michael Ong. Frédéric Pouliot. Ricardo A Rendon. Steven Yip. Anousheh Zardan. Laura Park-Wyllie. Huong Hew.

Introduction: The management of prostate cancer (PCa) continues to evolve with the emergence of new diagnostic and therapeutic strategies, resulting in areas that lack high-level evidence to guide practice. Consensus initiatives can establish practice guidance where evidence is unclear. The Genitourinary Research Consortium (GURC) recently conducted a 2nd Canadian Consensus Forum (“Forum”) to address controversial topics in the management of prostate cancer. 

Methods: A core planning group of multidisciplinary physicians (n=8) identified topics for discussion and developed questions for the Forum, which included a voting panel of physicians from academic institutions across Canada. Questions spanned across the disease continuum with a focus on management of oligometastatic/metastatic disease, novel imaging, and genomic testing. The threshold for ‘consensus agreement’ was set at 75%, and ‘disagreement’ was <50%.  The Forum was conducted in 2 parts, 51 questions were voted upon prior to the live Forum and 75 questions were discussed during the live Forum.

Results: The voting panel of 29 physicians included urologists/uro-oncologists (n=12), medical oncologists (n=12), radiation oncologists (n=5). Of the 75 live questions, 37 reached consensus agreement, and 12 were areas of disagreement. Of the 51 online questions administered prior to the live forum, 18 questions reached consensus. Consensus was seen in the use of ARAT and docetaxel in mCSPC, imaging modalities for staging, and use of genomic testing to manage metastatic disease.  The top 10 areas of consensus from the live forum are shown in Table 1.  Additional areas of agreement and disagreement will be reported.

Conclusions: A Canadian Consensus Forum in PCa identified consensus agreement across 44% of questions. Areas of variability represent opportunities for further research, education, and sharing of best practices. These findings reinforce the value of multidisciplinary consensus initiatives to optimize patient care.

© 2022 CUA 74th Annual Meeting